TOTAL: $218.96M | ||||
Company (Symbol)# |
Type Of Financing | Number Of Shares, Units Or Warrants (M) |
Amount Raised ($M)* |
Investors; Placement Agents; Details (Date)@ |
Amylin Pharmaceuticals Inc. (AMLN) | Private placement of common stock |
3.7S |
$18.5 | Amylin raised $18.5M in a private placement of 3.7M shares of common stock at $5 per share; investors included members of the company's board of directors and their affiliated funds (10/7) |
Aphton Corp. (APHT) |
Private placement of common stock |
0.8S |
$11.2 |
Aphton raised $11.2M in a private placement of 0.8M shares of common stock, at $14 per share, to an undisclosed institutional investor; the share price of $14 was the market price at the time the terms were negotiated (10/13) |
Cell Pathways Inc. (CLPA) | Private placement of common stock |
1.5S |
$14 | Cell Pathways raised $14M in a private placement of common stock at $9 per share; for each share purchased, the buyers also received one warrant enabling them to purchase an additional share of common stock at $14 per share; placement agent was Janney Montgomery Scott; other participants included four funds managed by Morgan Stanley Dean Witter Investment, including the Van Kampen American Value Fund; one fund managed by Miller, Anderson & Sherrerd LLP; and two funds managed by AIG Capital Management; previous investors included Vulcan Ventures Inc. and Jackson Boulevard Capital Management (10/11) |
Corvas International Inc. (CVAS) | Private placement of common stock and securities |
0.7S |
$5.25 | Corvas raised $5.25M from four investors; $3.5M was raised from the sale of securities to Artisan Equity Ltd.; $1.75M was raised from the sale of 0.7M shares of common stock to Sofinov (Societe financiere d'innovation), Finsbury Technology Trust and a fund associated with Wanger Asset Management (10/22) |
Cubist Pharmaceuticals Inc. (CBST) | Private placement of common stock |
2.5S | $18.8 | Cubist raised $18.8M in a private placement of common stock at $7.50 per share; Pacific Growth Equities acted as placement agent; other investors included new and existing shareholders (10/15) |
Geron Corp. (GERN) | Sale of convertible debentures and warrants | ND | $12.5 |
Geron entered into an agreement with an ND institutional investor to sell $12.5M in convertible debentures; the debentures are convertible by the investor at a fixed conversion price of $10.25 per share; the debentures convert at the company's option when the common stock has a traded at a certain premium to the fixed conversion price for five consecutive trading days; the investor will receive warrants to purchase up to 1.1M shares of common stock at a premium to the current market price; the warrants will expire 18 months following the closing (10/1) |
Helix BioMedix Inc. (OTC BB:HXBM) |
Private equity financing | ND | $2 | Helix completed a private placement of approximately $2M in equity financing; further details ND (10/20) |
ID Biomedical Corp. (Canada; TSE:IDB; IDBE) |
Private placement of warrants |
2W | C$5.5 (US$3.76) | ID Biomedical raised C$5.5M (US$3.76) in a private placement of special warrants to an undisclosed investor; each warrant will be exercisable, without additional payment, into one common share and one-half of one common share purchase warrant; each whole warrant will entitle the holder to purchase an additional common share at the price of C$2.75 (US$1.88) per share for a period of three years after the closing date of the issuance of the warrants (10/1) |
The Immune Response Corp. (IMNR) | Private placement of common stock | 0.6S |
$3 | Immune Response raised $3M in a private placement of 0.6M shares of common stock, at $5.06 per share, to an undisclosed institutional investor; the final number of shares to be issued to the investor will be determined by using a price equal to a 6 percent discount to the average trading price of the company's common stock during the 20 trading days following the sale of the shares; the company has agreed to sell the investor an additional $2.5M of common stock with no obligation to buy (10/22) |
Inhale Therapeutic Systems Inc. (INHL) |
Private placement of convertible subordinated debentures | ND |
$100 | Inhale entered into a purchase agreement providing for the sale to certain initial purchasers of $100M aggregate principal amount of convertible subordinated debentures ($109M if the overallotment option is exercised in full); the offering was made to qualified institutional buyers and a limited number of accredited investors; interest on the debentures will accrue at a rate of 6.75% per year, subject to adjustment in certain circumstances; the debentures will mature in 2006 and will be convertible into shares of Inhale's common stock at a conversion price of $32.01 per share (10/7) |
Lorus Therapeutics Inc. (Canada; TSE:LOR; LORFF) | Private placement of warrants | 30.3W | C$10 (US$6.83) | Lorus completed a private placement of 30.3M special warrants at a price of C$0.33 (US$0.23) per warrant; each warrant will entitle the holder to acquire, subject to adjustment, one share of common stock; HSBC Securities Inc. acted as lead agent; lead investor was Royal Bank Capital Corp. (10/28) |
Transkaryotic Therapies Inc. (TKTX) |
Private investment in a public entity (PIPE) | $132 |
Transkaryotic entered into purchase agreements for the sale of 3.3M shares of common stock in a PIPE financing to selected institutional and other accredited investors; share price was $40; Pacific Growth Equities acted as placement agent (10/29) | |
VaxGen Inc. (VXGN) | Private placement of common stock |
ND |
$25 | VaxGen completed a private placement of common stock to Vulcan Ventures Inc., the investment organization of Paul G. Allen, chairman of Vulcan; further details ND (10/12) |
Notes: | ||||
@ The dates listed indicate the issue dates of press releases. | ||||
* Conversion rate of C$1 = US$0.68; ND = Information not disclosed. | ||||
# Unless otherwise indicated, the stock symbols listed are on the Nasdaq Market. | ||||
To read more on related topics, click on one of the words below.